Crescita Reports Q4 and Fiscal 2023 Results
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 (“Q4-2023” and “F2023”).
- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 (“Q4-2023” and “F2023”).
- Commenting on the Company's results for the fourth quarter and full year 2023, Crescita's President and Chief Executive Officer, Serge Verreault, said:
“2023 was a challenging year for Crescita, marked by headwinds in our manufacturing segment. - Certain manufacturing orders initially scheduled to be delivered in the second half of fiscal 2023 were, in part, deferred to 2024, and some cancelled, contributing to a material decrease in our manufacturing segment revenue for Q4-2023 and fiscal 2023, compared to the same periods of 2022.
- During fiscal 2023, 719,203 Common Shares were repurchased for cancellation, at an average price of $0.55 per share for total cash consideration of $393.